Stocks Health care SKYE
NASDAQ · Health careSkye Bioscience, Inc. (SKYE)
It posted a net loss of $50.5M. In fiscal 2025 capital spending exceeded operating cash flow by $43.1M. At June 30, 2026 it held $8.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Skye Bioscience, Inc. does
Skye Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SKYE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$55.9M | -$1.41 | -$43.1M |
| 2024 | n/a | -$26.6M | -$0.73 | -$26.8M |
| 2023 | n/a | -$37.6M | -$5.37 | -$14M |
| 2022 | n/a | -$19.5M | -$8.77 | -$12.8M |
| 2021 | n/a | -$8.5M | -$4.39 | -$6.6M |
| 2020 | n/a | -$6.6M | -$6.58 | -$6.1M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Skye Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026Activist stake changed SCHEDULE 13D/A
- September 11, 2026Additional proxy material DEFA14A
- September 11, 2026
- August 24, 2026Additional proxy material DEFA14A
- August 24, 2026
- August 20, 2026Additional proxy material DEFA14A
- August 20, 2026
- August 19, 2026Additional proxy material DEFA14A
- August 19, 2026
- August 18, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Skye Bioscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $889.2K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 23, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 114,851 | $184.9K |
| September 23, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 4,528 | $7.3K |
| September 23, 2026 | Schwab Andrew J.Director, 10% owner | Soldindirect | 114,851 | $184.9K |
| September 23, 2026 | Schwab Andrew J.Director, 10% owner | Soldindirect | 4,528 | $7.3K |
| September 22, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 27,612 | $45.6K |
| September 22, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 1,088 | $1.8K |
| September 22, 2026 | Schwab Andrew J.Director, 10% owner | Soldindirect | 27,612 | $45.6K |
| September 22, 2026 | Schwab Andrew J.Director, 10% owner | Soldindirect | 1,088 | $1.8K |
| September 16, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 32,607 | $62.3K |
| September 16, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 1,285 | $2.5K |
| September 16, 2026 | Schwab Andrew J.Director, 10% owner | Soldindirect | 32,607 | $62.3K |
| September 16, 2026 | Schwab Andrew J.Director, 10% owner | Soldindirect | 1,285 | $2.5K |
| August 20, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 1,159 | $370.9 |
| August 20, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 46 | $14.7 |
| August 20, 2026 | 5AM Partners VII, LLC10% owner | Soldindirect | 6,495 | $2.1K |
Who owns SKYE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Andrew J. Schwab13D, may seek influence with 8 related filers | 26.1% | September 24, 2026 |
Largest institutional holders
Insiders
1 insiders reported holding 1,419,823 shares in total, about $2.4M at the last price.
| Holder | Shares |
|---|---|
| Dhillon PunitChief Executive Officer, Director | 1,419,823 |
Questions about SKYE
What does Skye Bioscience, Inc. do?
Skye Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SKYE.
Is Skye Bioscience, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $50.5M.
When did Skye Bioscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the activist stake changed from September 24, 2026.
Similar companies
Compare SKYE with
Follow SKYE
Get an email when Skye Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SKYE: get an email when it filesWhere the numbers come from
Financial figures are the values Skye Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.